sarafloxacin hydrochloride profile

Sarafloxacin hydrochloride is a synthetic fluoroquinolone antibiotic. It is a potent inhibitor of bacterial DNA gyrase and topoisomerase IV, enzymes essential for bacterial DNA replication and repair. Sarafloxacin is effective against a broad spectrum of Gram-positive and Gram-negative bacteria, including strains resistant to other antibiotics. It is used to treat various bacterial infections in humans and animals. Research into sarafloxacin focuses on its antimicrobial activity, pharmacokinetic properties, and potential therapeutic applications. For example, studies have investigated its effectiveness in treating respiratory tract infections, urinary tract infections, and skin infections. It is also being explored for its potential use in treating other conditions, such as tuberculosis and malaria.'

ID Source	ID
PubMed CID	56207
CHEMBL ID	542157
MeSH ID	M0322558

Synonym
sarafloxacin hydrochloride
saraflox
abbott-56620
a-57135
91296-87-6
a-56620
a 56620
D05802
sarafloxacin hydrochloride (usan)
saraflox wsp (tn)
NCGC00095163-02
NCGC00095163-01
SPECTRUM1505314
sarafloxacin monohydrochloride
sarafin
nsc-758956
abbott-57135 [sarafloxacin]
sarafloxacin hcl
CHEMBL542157
HMS1922D04
6-fluoro-1-(4-fluorophenyl)-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid hydrochloride
6-fluoro-1-(4-fluorophenyl)-4-oxo-7-piperazin-1-yl-quinoline-3-carboxylic acid hydrochloride
A843795
saraflox injectable
nsc 758956
unii-i36jp4q9df
sarafloxacin hydrochloride [usan]
abbott 56620
3-quinolinecarboxylic acid, 6-fluoro-1-(4-fluorophenyl)-1,4-dihydro-4-oxo-7-(1-piperazinyl)-, monohydrochloride
saraflox wsp
6-fluoro-1-(p-fluorophenyl)-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid monohydrochloride
i36jp4q9df ,
n-methyl-1,2,3,6-tetrahydropyridine hydrochloride
nsc758956
pharmakon1600-01505314
dtxcid6025939
dtxsid8045939 ,
cas-91296-87-6
tox21_111462
AKOS016013115
CCG-39997
6-fluoro-1-(4-fluorophenyl)-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid hydrochloride
6-fluoro-1-(4-fluorophenyl)-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride
FT-0630976
S1977
sarafloxacin hydrochloride [green book]
abbott-57135 hydrochloride
sarafloxacin hydrochloride [mart.]
3-quinolinecarboxylic acid, 6-fluoro-1-(4-fluorophenyl)-1,4-dihydro-4-oxo-7-(1-piperazinyl)-, hydrochloride (1:1)
sarafloxacin monohydrochloride [mi]
sarafloxacin (hydrochloride)
HY-B0343A
NCGC00177995-02
tox21_111462_1
sarafloxacin hydrochloride, antibiotic for culture media use only
S-0500
S0840
a-56620 (hydrochloride)
a-56620 hcl
6-fluoro-1-(4-fluorophenyl)-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid hydrochloride (1:1); 3-quinolinecarboxylic acid, 6-fluoro-1-(4-fluorophenyl)-1,4-dihydro-4-oxo-7-(1-piperazinyl)-, monohydrochloride (9ci); sarafin; sarafloxacin hy
1352879-52-7
6-fluoro-1-(4-fluorophenyl)-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid;hydrochloride
6-fluoro-1-(4-fluorophenyl)-4-oxo-7-piperazin-1-yl-1,4-dihydroquinoline-3-carboxylic acid hydrochloride
AS-16087
BCP13147
3-quinolinecarboxylic acid,6-fluoro-1-(4-fluorophenyl)-1,4-dihydro-4-oxo-7-(1-piperazinyl)-,monohydrochloride
FT-0674520
mfcd03427297
Q27280302
6-fluoro-1-(4-fluorophenyl)-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid . hydrochloride
1ST5757AD8

Excerpt	Reference	Relevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, HADH2 protein	Homo sapiens (human)	Potency	25.1189	0.0251	20.2376	39.8107	AID893
Chain B, HADH2 protein	Homo sapiens (human)	Potency	25.1189	0.0251	20.2376	39.8107	AID893
Chain A, 2-oxoglutarate Oxygenase	Homo sapiens (human)	Potency	25.1189	0.1778	14.3909	39.8107	AID2147
TDP1 protein	Homo sapiens (human)	Potency	19.1480	0.0008	11.3822	44.6684	AID686978; AID686979
AR protein	Homo sapiens (human)	Potency	21.8268	0.0002	21.2231	8,912.5098	AID743035; AID743063
aldehyde dehydrogenase 1 family, member A1	Homo sapiens (human)	Potency	25.1189	0.0112	12.4002	100.0000	AID1030
cytochrome P450 family 3 subfamily A polypeptide 4	Homo sapiens (human)	Potency	18.9991	0.0123	7.9835	43.2770	AID1645841
estrogen nuclear receptor alpha	Homo sapiens (human)	Potency	22.6142	0.0002	29.3054	16,493.5996	AID743069; AID743078
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1	Homo sapiens (human)	Potency	28.1838	0.0018	15.6638	39.8107	AID894
vitamin D3 receptor isoform VDRA	Homo sapiens (human)	Potency	100.0000	0.3548	28.0659	89.1251	AID504847
lamin isoform A-delta10	Homo sapiens (human)	Potency	2.2387	0.8913	12.0676	28.1838	AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (82)

Assay ID	Title	Year	Journal	Article
AID1508627	Counterscreen qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: GLuc-NoTag assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508628	Confirmatory qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347425	Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508629	Cell Viability qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424	RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347407	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID504749	qHTS profiling for inhibitors of Plasmodium falciparum proliferation	2011	Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043	Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID206539	Compound was evaluated in vivo for antibacterial activity against Staphylococcus aureus NCTC 10649 (100 X LD50) (s.c. administration); Range is between (1.0-2.5)	1987	Journal of medicinal chemistry, Mar, Volume: 30, Issue:3	Synthesis and structure-activity relationship of 1-aryl-6,8-difluoroquinolone antibacterial agents.
AID164076	Compound was evaluated in vivo for antibacterial activity against Pseudomonas aeruginosa 5007 (100 X LD50) (p.o. administration); Range is between (13.4-34.4)	1987	Journal of medicinal chemistry, Mar, Volume: 30, Issue:3	Synthesis and structure-activity relationship of 1-aryl-6,8-difluoroquinolone antibacterial agents.
AID164560	In vitro antibacterial activity against Pseudomonas aeruginosa 5007	1986	Journal of medicinal chemistry, Nov, Volume: 29, Issue:11	Synthesis and structure-activity relationships of new arylfluoronaphthyridine antibacterial agents.
AID164561	In vitro antibacterial activity against Pseudomonas aeruginosa K799/WT	1986	Journal of medicinal chemistry, Nov, Volume: 29, Issue:11	Synthesis and structure-activity relationships of new arylfluoronaphthyridine antibacterial agents.
AID70418	In vitro antibacterial activity against Escherichia coli Juhl	1986	Journal of medicinal chemistry, Nov, Volume: 29, Issue:11	Synthesis and structure-activity relationships of new arylfluoronaphthyridine antibacterial agents.
AID164555	In vitro antibacterial activity against Pseudomonas aeruginosa K799/WT	1987	Journal of medicinal chemistry, Mar, Volume: 30, Issue:3	Synthesis and structure-activity relationship of 1-aryl-6,8-difluoroquinolone antibacterial agents.
AID164564	Compound was evaluated in vivo for antibacterial activity against Pseudomonas aeruginosa 5007 (100 X LD50);	1987	Journal of medicinal chemistry, Mar, Volume: 30, Issue:3	Synthesis and structure-activity relationship of 1-aryl-6,8-difluoroquinolone antibacterial agents.
AID113337	In vivo dose(po) inhibiting systemic infections caused by Escherichia coli Juhl in mice.	1986	Journal of medicinal chemistry, Nov, Volume: 29, Issue:11	Synthesis and structure-activity relationships of new arylfluoronaphthyridine antibacterial agents.
AID209294	In vitro antibacterial activity against Streptococcus pyogenes 930	1987	Journal of medicinal chemistry, Mar, Volume: 30, Issue:3	Synthesis and structure-activity relationship of 1-aryl-6,8-difluoroquinolone antibacterial agents.
AID164563	Compound was evaluated in vivo for antibacterial activity against Pseudomonas aeruginosa 5007 (100 X LD50)	1987	Journal of medicinal chemistry, Mar, Volume: 30, Issue:3	Synthesis and structure-activity relationship of 1-aryl-6,8-difluoroquinolone antibacterial agents.
AID67685	In vitro antibacterial activity against Enterobacter aerogenes ATCC 13048	1986	Journal of medicinal chemistry, Nov, Volume: 29, Issue:11	Synthesis and structure-activity relationships of new arylfluoronaphthyridine antibacterial agents.
AID30422	In vitro antibacterial activity against Acinetobacter species CMX669	1986	Journal of medicinal chemistry, Nov, Volume: 29, Issue:11	Synthesis and structure-activity relationships of new arylfluoronaphthyridine antibacterial agents.
AID207963	Compound was evaluated in vivo for antibacterial activity against Staphylococcus aureus NCTC 10649 (100 X LD50)	1987	Journal of medicinal chemistry, Mar, Volume: 30, Issue:3	Synthesis and structure-activity relationship of 1-aryl-6,8-difluoroquinolone antibacterial agents.
AID113343	In vivo dose(sc) inhibiting systemic infections caused by Escherichia coli Juhl in mice.	1986	Journal of medicinal chemistry, Nov, Volume: 29, Issue:11	Synthesis and structure-activity relationships of new arylfluoronaphthyridine antibacterial agents.
AID207961	In vitro antibacterial activity against Staphylococcus aureus CMX 686B	1986	Journal of medicinal chemistry, Nov, Volume: 29, Issue:11	Synthesis and structure-activity relationships of new arylfluoronaphthyridine antibacterial agents.
AID113347	In vivo dose(sc) inhibiting systemic infections caused by Staphylococcus aureus NCTC 10649 in mice.	1986	Journal of medicinal chemistry, Nov, Volume: 29, Issue:11	Synthesis and structure-activity relationships of new arylfluoronaphthyridine antibacterial agents.
AID115942	In vivo antibacterial activity against systemic infection caused by Staphylococcus aureus NCTC 10649 in mice.	1986	Journal of medicinal chemistry, Nov, Volume: 29, Issue:11	Synthesis and structure-activity relationships of new arylfluoronaphthyridine antibacterial agents.
AID67684	In vitro antibacterial activity against Enterobacter aerogenes ATCC 13048	1987	Journal of medicinal chemistry, Mar, Volume: 30, Issue:3	Synthesis and structure-activity relationship of 1-aryl-6,8-difluoroquinolone antibacterial agents.
AID115940	In vivo antibacterial activity against systemic infection caused by Pseudomonas aeruginosa 5007 in mice.	1986	Journal of medicinal chemistry, Nov, Volume: 29, Issue:11	Synthesis and structure-activity relationships of new arylfluoronaphthyridine antibacterial agents.
AID977602	Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID113341	In vivo dose(po) inhibiting systemic infections caused by Staphylococcus aureus NCTC 10649 in mice.	1986	Journal of medicinal chemistry, Nov, Volume: 29, Issue:11	Synthesis and structure-activity relationships of new arylfluoronaphthyridine antibacterial agents.
AID70409	In vitro antibacterial activity against Escherichia coli Juhl	1987	Journal of medicinal chemistry, Mar, Volume: 30, Issue:3	Synthesis and structure-activity relationship of 1-aryl-6,8-difluoroquinolone antibacterial agents.
AID164554	In vitro antibacterial activity against Pseudomonas aeruginosa 5007	1987	Journal of medicinal chemistry, Mar, Volume: 30, Issue:3	Synthesis and structure-activity relationship of 1-aryl-6,8-difluoroquinolone antibacterial agents.
AID209298	In vitro antibacterial activity against Streptococcus pyogenes 930	1986	Journal of medicinal chemistry, Nov, Volume: 29, Issue:11	Synthesis and structure-activity relationships of new arylfluoronaphthyridine antibacterial agents.
AID68806	Compound was evaluated in vivo for antibacterial activity against Escherichia coli Juhl (100 X LD50) (s.c. administration); Range is between (0.3-1.3)	1987	Journal of medicinal chemistry, Mar, Volume: 30, Issue:3	Synthesis and structure-activity relationship of 1-aryl-6,8-difluoroquinolone antibacterial agents.
AID95881	In vitro antibacterial activity against Klebsiella pneumoniae 8045	1986	Journal of medicinal chemistry, Nov, Volume: 29, Issue:11	Synthesis and structure-activity relationships of new arylfluoronaphthyridine antibacterial agents.
AID164078	Compound was evaluated in vivo for antibacterial activity against Pseudomonas aeruginosa 5007 (100 X LD50) (s.c. administration); Range is between (1.0-2.5)	1987	Journal of medicinal chemistry, Mar, Volume: 30, Issue:3	Synthesis and structure-activity relationship of 1-aryl-6,8-difluoroquinolone antibacterial agents.
AID207944	In vitro antibacterial activity against Staphylococcus aureus CMX 686B	1987	Journal of medicinal chemistry, Mar, Volume: 30, Issue:3	Synthesis and structure-activity relationship of 1-aryl-6,8-difluoroquinolone antibacterial agents.
AID68805	Compound was evaluated in vivo for antibacterial activity against Escherichia coli Juhl (100 X LD50) (p.o. administration); Range is between (2.8-6.5)	1987	Journal of medicinal chemistry, Mar, Volume: 30, Issue:3	Synthesis and structure-activity relationship of 1-aryl-6,8-difluoroquinolone antibacterial agents.
AID96096	In vitro antibacterial activity against Klebsiella pneumoniae 8045	1987	Journal of medicinal chemistry, Mar, Volume: 30, Issue:3	Synthesis and structure-activity relationship of 1-aryl-6,8-difluoroquinolone antibacterial agents.
AID206215	In vitro antibacterial activity against Staphylococcus epidermis 3519	1987	Journal of medicinal chemistry, Mar, Volume: 30, Issue:3	Synthesis and structure-activity relationship of 1-aryl-6,8-difluoroquinolone antibacterial agents.
AID209567	In vitro antibacterial activity against Streptococcus faecium ATCC 8043	1987	Journal of medicinal chemistry, Mar, Volume: 30, Issue:3	Synthesis and structure-activity relationship of 1-aryl-6,8-difluoroquinolone antibacterial agents.
AID205588	In vitro antibacterial activity against Staphylococcus epidermidis 3519	1986	Journal of medicinal chemistry, Nov, Volume: 29, Issue:11	Synthesis and structure-activity relationships of new arylfluoronaphthyridine antibacterial agents.
AID207943	In vitro antibacterial activity against Staphylococcus aureus ATCC 6538P	1987	Journal of medicinal chemistry, Mar, Volume: 30, Issue:3	Synthesis and structure-activity relationship of 1-aryl-6,8-difluoroquinolone antibacterial agents.
AID68972	Compound was evaluated in vivo for antibacterial activity against Escherichia coli Juhl (100 X LD50) (p.o. administration); Range is between (3.8-11.2)	1987	Journal of medicinal chemistry, Mar, Volume: 30, Issue:3	Synthesis and structure-activity relationship of 1-aryl-6,8-difluoroquinolone antibacterial agents.
AID115938	In vivo antibacterial activity against systemic infection caused by Escherichia coli Juhl in mice.	1986	Journal of medicinal chemistry, Nov, Volume: 29, Issue:11	Synthesis and structure-activity relationships of new arylfluoronaphthyridine antibacterial agents.
AID30270	In vitro antibacterial activity against Acinetobacter CMX 669	1987	Journal of medicinal chemistry, Mar, Volume: 30, Issue:3	Synthesis and structure-activity relationship of 1-aryl-6,8-difluoroquinolone antibacterial agents.
AID113345	In vivo dose(sc) inhibiting systemic infections caused by Pseudomonas aeruginosa 5007 in mice.	1986	Journal of medicinal chemistry, Nov, Volume: 29, Issue:11	Synthesis and structure-activity relationships of new arylfluoronaphthyridine antibacterial agents.
AID209569	In vitro antibacterial activity against Streptococcus faecium ATCC 8043	1986	Journal of medicinal chemistry, Nov, Volume: 29, Issue:11	Synthesis and structure-activity relationships of new arylfluoronaphthyridine antibacterial agents.
AID113339	In vivo dose(po) inhibiting systemic infections caused by Pseudomonas aeruginosa 5007 in mice.	1986	Journal of medicinal chemistry, Nov, Volume: 29, Issue:11	Synthesis and structure-activity relationships of new arylfluoronaphthyridine antibacterial agents.
AID977599	Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID207960	In vitro antibacterial activity against Staphylococcus aureus ATCC 6538P	1986	Journal of medicinal chemistry, Nov, Volume: 29, Issue:11	Synthesis and structure-activity relationships of new arylfluoronaphthyridine antibacterial agents.
AID540299	A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis	2010	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21	Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519	A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities	2011	Antiviral research, Sep, Volume: 91, Issue:3	High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1159550	Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening	2015	Nature cell biology, Nov, Volume: 17, Issue:11	6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	2 (12.50)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	8 (50.00)	24.3611
2020's	6 (37.50)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (6.25%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	15 (93.75%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
ciprofloxacin Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.. ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.	2.37	2	aminoquinoline; cyclopropanes; fluoroquinolone antibiotic; N-arylpiperazine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone; zwitterion	antibacterial drug; antiinfective agent; antimicrobial agent; DNA synthesis inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; environmental contaminant; topoisomerase IV inhibitor; xenobiotic
norfloxacin Norfloxacin: A synthetic fluoroquinolone (FLUOROQUINOLONES) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA GYRASE.. norfloxacin : A quinolinemonocarboxylic acid with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase.	2.37	2	fluoroquinolone antibiotic; N-arylpiperazine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone	antibacterial drug; DNA synthesis inhibitor; environmental contaminant; xenobiotic
tosufloxacin tosufloxacin: quinolone anti-infective agent; structure given in first source. tosufloxacin : A racemate comprising equimolar amounts of (R)- and (S)-tosufloxacin.. 7-(3-aminopyrrolidin-1-yl)-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid : A 1,8-naphthyridine derivative that is 4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid bearing additional 2,4-difluorophenyl, fluoro and 3-aminopyrrolidin-1-yl substituents at positions 1, 6 and 7 respectively.	1.96	1	1,8-naphthyridine derivative; amino acid; aminopyrrolidine; monocarboxylic acid; organofluorine compound; primary amino compound; quinolone antibiotic; tertiary amino compound
difloxacin hydrochloride [no description available]	1.96	1
difloxacin difloxacin: RN & structure given in first source. difloxacin : A quinolone that is pefloxacin in which the ethyl group at position 1 of the quinolone has been replaced by a p-fluorophenyl group. A broad-spectrum antibiotic effective against both Gram-positive and Gram-negative bacteria, it is used (usually as the monohydrochloride salt) for the treatment of bacterial infections in dogs.	1.97	1	fluoroquinolone antibiotic; monocarboxylic acid; monofluorobenzenes; N-alkylpiperazine; N-arylpiperazine; quinolone antibiotic; quinolone	antibacterial drug; Mycoplasma genitalium metabolite

Condition	Relationship Strength	Studies
Bacterial Disease [description not available]	1.97	1
Bacterial Infections Infections by bacteria, general or unspecified.	1.97	1
Encephalitis, Polio [description not available]	2.06	1
Poliomyelitis An acute infectious disease of humans, particularly children, caused by any of three serotypes of human poliovirus (POLIOVIRUS). Usually the infection is limited to the gastrointestinal tract and nasopharynx, and is often asymptomatic. The central nervous system, primarily the spinal cord, may be affected, leading to rapidly progressive paralysis, coarse FASCICULATION and hyporeflexia. Motor neurons are primarily affected. Encephalitis may also occur. The virus replicates in the nervous system, and may cause significant neuronal loss, most notably in the spinal cord. A rare related condition, nonpoliovirus poliomyelitis, may result from infections with nonpoliovirus enteroviruses. (From Adams et al., Principles of Neurology, 6th ed, pp764-5)	2.06	1
Benign Neoplasms [description not available]	3.03	1
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	3.03	1
Congenital Zika Syndrome [description not available]	2.25	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.25	1
Zika Virus Infection A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.	2.25	1

sarafloxacin hydrochloride

Cross-References

Synonyms (71)

Research Excerpts

Bioavailability

Protein Targets (11)

Potency Measurements

Bioassays (82)

Research

Studies (16)

Market Indicators

Research Demand Index: 22.20

Study Types

sarafloxacin hydrochloride

Cross-References

Synonyms (71)

Research Excerpts

Bioavailability

Protein Targets (11)

Potency Measurements

Bioassays (82)

Research

Studies (16)

Market Indicators

Research Demand Index: 22.20

Study Types

Related Drugs (5)

Related Conditions (9)